Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Yoon Ho Ko

Citation

Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523

Authors

Y.H. Ko1, D.S. Sun2, H.S. Won2, M.A. Lee3, S.U. Hong4, J. Jung5, H. Cho6, B. Shim7

Author affiliations

  • 1 Medical Oncology, Uijeongbu St. Mary's Hospital, 480-717 - Uijeongbu City/KR
  • 2 Medical Oncology, Uijeongbu St. Mary's Hospital, Uijeongbu City/KR
  • 3 Medical Oncology, Seoul St. Mary's Hospital, of the Catholic University, Seoul/KR
  • 4 Pathology, Chung-Ang University Hospital, Seoul/KR
  • 5 Pathology, St Vincent Hospital The Catholic University of Korea, Suwon/KR
  • 6 Surgery, St Vincent Hospital The Catholic University of Korea, Suwon/KR
  • 7 Medical Oncology, St Vincent Hospital The Catholic University of Korea, 442-723 - Suwon/KR
More

Resources

Aim/Background

Autophagy, a cellular degradation process, has complex roles in tumourigenesis and resistance to cancer treatment in humans. The aim of this study was to explore the expression levels of autophagy-related proteins in patients with rectal cancer and evaluate their clinical role in the neoadjuvant chemoradiotherapy setting.

Methods

All specimens evaluated were obtained from 101 patients with colorectal cancer who had undergone neoadjuvant chemoradiotherapy and curative surgery. The primary outcomes measured were the expression levels of two autophagy-related proteins (microtubule-associated protein 1 light chain 3 beta (LC3b) and beclin-1) by immunohistochemistry and their association with clinicopathological parameters and patient survival.

Results

Among the 101 patients, the frequency of high expression of beclin-1 was 31.7% (32/101) and that of LC3b was 46.5% (47/101). A pathologic complete response was inversely associated with LC3b expression (P = 0.003) and alterations in the expression of autophagy-related proteins (P = 0.046). In the multivariate analysis, however, autophagy-related protein expression did not show prognostic significance for relapse-free survival or overall survival.

Conclusions

High expression of autophagy-related proteins shows a strong negative association with the efficacy of neoadjuvant chemoradiotherapy in patients with rectal cancer. Autophagy has clear implications as a therapeutic target with which to improve the efficacy of neoadjuvant chemoradiotherapy.

Clinical trial identification

nothing to declare

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings